Multicenter prospective observational study to evaluate immune cell dynamics of EGFR tyrosine kinase inhibitor re-administration after administration of immune checkpoint inhibitor in patients with relapsed / advanced non-small cell lung cancer with EGFR gene mutatio
Not Applicable
Recruiting
- Conditions
- relapsed / advanced non-small cell lung cancer with EGFR gene mutation
- Registration Number
- JPRN-UMIN000039182
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with interstitial lung disease or a history of it. 2) HBs antigen positive. 3) HBs antibody or HBc antibody positive and HBV-DNA positive. 4) HCV carrier. 5) Serious complications. 6) A history of severe hypersensitivity. 7) The principal investigator or the research coordinator determined that participation in this study was inappropriate.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in immune cell dynamics by EGFR-TKI administration
- Secondary Outcome Measures
Name Time Method